GlassScriptPhysician profile
Bruce S Kovan
NPI 1265494595
$13,722.97
in general payments reported to CMS, 2019-2025
45 companies · $2,158 in 2025
The $2,158 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,186 · 2020: $289 · 2021: $1,106 · 2022: $2,202 · 2023: $2,174 · 2024: $2,608 · 2025: $2,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,840 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,840.48 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,586.77 | 2019-2025 | |
| Allergan, INC. | $1,744.44 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,173.50 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,045.74 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $932.15 | 2019-2025 | |
| Janssen Biotech, INC. | $760.72 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $666.82 | 2019-2025 | |
| Ardelyx, INC. | $419.11 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $360.41 | 2022-2025 | Dupixent |
| Genzyme Corporation | $340.44 | 2022-2025 | |
| Celgene Corporation | $315.71 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $263.17 | 2020-2025 | Ocaliva |
| Qol Medical, LLC | $242.48 | 2019-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $160.02 | 2019-2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $159.21 | 2021-2023 | Rebyota |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $151.65 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $144.79 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $112.32 | 2021-2024 | Injectafer |
| Amgen INC. | $110.63 | 2022-2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $95.58 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $93.77 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $92.53 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $89.45 | 2021-2023 | |
| Redhill Biopharma INC. | $80.87 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Evoke Pharma, INC. | $75.14 | 2021-2022 | |
| Organon LLC | $52.13 | 2023-2024 | Renflexis, Hadlima |
| Capsovision, INC. | $46.05 | 2023-2024 | Capsocam Plus |
| Phathom Pharmaceuticals, INC. | $39.52 | 2024-2025 | Voquezna |
| Ucb, INC. | $35.78 | 2019 | |
| Fresenius Kabi USA, LLC | $31.14 | 2023 | |
| Medtronic, INC. | $30.47 | 2021 | |
| Novo Nordisk INC | $26.37 | 2020-2025 | Wegovy |
| Mauna Kea Technologies, INC. | $26.07 | 2024 | |
| Celltrion USA INC. | $24.68 | 2025 | Vegzelma |
| Mylan Institutional INC. | $22.65 | 2023 | Hulio |
| W. L. Gore & Associates, INC. | $21.68 | 2023 | Gore Cardioform Septal Occluder |
| Micro-Tech Endoscopy USA, INC. | $18.92 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.75 | 2021 | |
| Boston Scientific Corporation | $17.97 | 2023 | Wavewriter Alpha Prime 16 |
| Alexion Pharmaceuticals, INC. | $16.69 | 2019 | |
| Echosens North America, INC. | $16.27 | 2019 | |
| Lucid Diagnostics INC. | $15.93 | 2024 | |
| Vivus LLC | $15.55 | 2024 | Qsymia |
| Exact Sciences Corporation | $14.66 | 2025 | Cologuard Collection Kit |
| Romark Laboratories, Lc | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Kovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.